Across TCGA pan-cancer cohorts, MROH2A Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MROH2A data layer compared with 26 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MROH2A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MROH2A expression acts as an unfavorable survival marker.

LIHC are the cancer types where MROH2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: MROH2A tumor-vs-normal RNA expression · all MROH2A data types